期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

绝经后激素受体阳性乳腺癌新辅助内分泌治疗的若干问题 被引量：5

原文传递
导出
摘要 新辅助内分泌治疗是指在计划的手术治疗前进行一段时间内分泌治疗的辅助治疗方式，最早的研究报道可追溯到1986年。与新辅助化疗相比，新辅助内分泌治疗的临床研究相对较少。目前在临床应用方面，新辅助内分泌治疗用于局部进展期乳腺癌获得手术机会，或可手术乳腺癌获得保留乳房手术机会。还用于临床对照研究和预测性指标研究。
作者 欧阳涛
机构地区 北京大学肿瘤医院乳腺癌预防治疗中心
出处 《中华医学杂志》 CAS CSCD 北大核心 2012年第20期1374-1375,共2页 National Medical Journal of China
关键词 新辅助内分泌治疗 可手术乳腺癌 激素受体 绝经后 阳性 新辅助化疗 局部进展期 手术机
分类号 R737.9 [医药卫生—肿瘤]
作者简介 欧阳涛,Email:ouyanghongtao@263.net
  • 相关文献

参考文献10

  • 1刘真真,卢振铎,刘慧,李连方,张恒伟,杨辉,李文亮,崔树德.甲氧基异丁基异腈肿瘤显像对可手术乳腺癌新辅助疗效的预测价值[J].中华医学杂志,2011,91(6):382-384. 被引量：3
  • 2姚舒洋,徐兵河,李青,张频,王佳玉,袁芃,马飞,蔡瑞刚.戈舍瑞林联合阿那曲唑治疗晚期绝经前乳腺癌的临床观察[J].中华医学杂志,2010,90(8):526-528. 被引量：16
  • 3祁萌,李金锋,解云涛,陆爱萍,刘毅强,林本耀,欧阳涛.乳腺癌新辅助化疗初期超声评效预测病理评价的可行性[J].中华医学杂志,2010,90(8):511-514. 被引量：8
  • 4汪星,何英剑,英旻,李金锋,解云涛,王天峰,范照青,范铁,欧阳涛.新辅助化疗后腋窝阳性淋巴结病理完全缓解对乳腺癌预后的影响[J].中华医学杂志,2011,91(30):2116-2119. 被引量：11
  • 5Kanfmann M, von-Minckwitz G, Bear HD, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol, 2007, 18 : 1927- 1934.
  • 6Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol,2009,20 : 1319-1329.
  • 7Colleoni M, Bagnardi V, Rotmensz N, et al. Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy. Breast Cancer Res Treat, 2009.116:359-369.
  • 8Iohnston SR,Semiglazov VF, Manikhas, GM, et al. A phase Ⅱ, randomized, blinded study of the farnesyhransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy. Breast cancer research and treatment, 2008,110:244-254.
  • 9Thomas JS, Julian HS, Green RV, et al. Histopathology of breast carcinoma following neoadjuvant systemic therapy: a common association between letrozole therapy and central scarring. Histopathology, 2007,51:219-226.
  • 10Ellis MJ, Lin L, Crowder, et al. Randomized phase Ⅱ neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031. J Clin Oncol, 2011,29:2342-2349.

二级参考文献44

  • 1刘真真,刘慧,李连方,崔树德.^(99m)Tc-MIBI显像在乳癌及腋窝淋巴结转移诊断应用[J].医药论坛杂志,2005,26(4):14-16. 被引量：5
  • 2崔树德,刘真真,刘慧,李连方,杨辉,李文亮.甲氧基乙丁基异腈亲肿瘤显像与乳腺癌多药耐药类蛋白关系的研究[J].中华肿瘤杂志,2005,27(10):606-608. 被引量：9
  • 3Parkin DM,Bray F,Ferlay J,et al.Global cancer statistics,2002.CA Cancer J Clin,2005,55:74-108.
  • 4Landis SH,Murray T,Bolden S,et al.Cancer statistics,1999.CA Cancer J Clin,1999,49:8-31.
  • 5Greeaberg PA,Hortobagyi GN,Smith TL,et al.Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer.J Clin Oncol,1996,14:2197-2205.
  • 6Forward DP,Cheung KL,Jackson L,et al.Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer.Br J Cancer,2004,90:590-594.
  • 7Carlson RW,Schurman CM,Rivera E,et al.Goserelin plus anastrozole for the treatment of premenopausal women with hormone receptor positive,recurrent/metastatic breast cancer.Breast Cancer Res Treat,2004,88:S237.
  • 8Therasse P,Arbuck SG,Eisenhauer EA,et al.New guidelines to evaluate the response to treatment in solid tumors.European Organization for Research and Treatment of Cancer,National Cancer Institute of the United States,National Cancer Institute of Canada.J Nail Cancer Inst,2000,92:205-216.
  • 9De Maio E,Gravina A,Pacilio C,et al.Compliance and toxicity of adjuvant CMF in elderly breast cancer patients:a single-center experience.BMC Cancer,2005,5:30.
  • 10Yang WT,Dryden MJ,Gwyn K,et al.Imaging of breast cancer diagnosed and treated with chemotherapy during pregnancy.Radiology,2006,239:52-60.

共引文献34

同被引文献73

  • 1罗建文,白净.超声弹性成像的研究进展[J].中国医疗器械信息,2005,11(5):23-31. 被引量：150
  • 2武正炎.ER阳性绝经后乳腺癌术后辅助内分泌治疗(BIG1-98研究结果解读)[J].实用临床医药杂志,2006,10(2):32-33. 被引量：8
  • 3余科达,狄根红,吴炅,陆劲松,沈坤炜,沈镇宙,邵志敏.ER(-)PR(+)乳腺癌辅助内分泌治疗的疗效[J].中国癌症杂志,2006,16(12):1011-1015. 被引量：13
  • 4Orlando L, Schiavone P, Fedele P, et al. Molecularly targetedendocrine therapies for breast cancer. Cancer Treat Rev, 2010,36:S67-71.
  • 5Helleman J, Jansen MP, Ruigrok-Ritstier K, et al. Association ofan extracellular matrix gene cluster with breast cancer prognosisand endocrine therapy response. Clin Cancer Res,2008,14 :5555-5564.
  • 6Generali D, Berruti A, Brizzi MP, et al. Hypoxia-induciblefactor-1 a expression predicts a poor response to primarychemoendocrine therapy and disease-free survival in primaryhuman breast cancer. Clin Cancer Res, 2006, 12:4562-4568.
  • 7Mita MM, Mita A, Rowinsky EK. Mammalian target ofrapamycin : a new molecular target for breast cancer. Clin BreastCancer, 2003,4:126-137.
  • 8Osborne CK,Schiff R. Mechanisms of endocrine resistance inbreast cancer . Annu Rev Med, 2011,62:233-247.
  • 9Miller WR. Identification and mechanisms of endocrine resistance.Breast Cancer Res, 2008 , 10:S19.
  • 10Alkner S, Bendahl PO, Grabau D, et al. AIB1 is a predictivefactor for tamoxifen response in premenopausal women. AnnOncol, 2010,21:238-244.

引证文献5

二级引证文献20

中华医学杂志
2012年 第20期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
关于我们 | 版权声明 | 联系我们 | 帮助中心| 意见反馈
主办单位：上海市教育委员会
技术支持：重庆维普资讯有限公司
渝公网安备 50019002500403号
使用帮助 返回顶部